The short answer
McKesson (MCK) is HALAL on ZakatInvest's qualitative healthcare-distribution assessment, but the result is methodology-dependent. McKesson distributes medicines, medical supplies and healthcare technology. Its current FTSE Yasaar and Malaysia SAC asset ratios pass, while the examined MSCI total-assets receivables-plus-cash ratio fails. Controlled-substance distribution, finance charges, customer concentration and historical opioid litigation remain qualitative questions.
This is a reproducible research screen, not a fatwa or investment recommendation. Scholars and screening providers can differ on receivables denominators, late fees, finance leases and downstream product use.
Current quantitative Sharia screen
Based on 10-K figures for the period ended 2026-03-31; calculated 2026-07-13.
6,526 / 82,323
3,975 / 82,323
31,960 / 82,323
179 / 403,430
- Financial
- Pass
- Overall
- Incomplete
Debt is 7.93%, liquidity is 4.83%, receivables plus cash are 38.85% and disclosed interest income is 0.04%; each is below the examined FTSE limits. Business activity remains incomplete because the filing does not quantify a universal prohibited-revenue numerator.
- Financial
- Fails
- Overall
- Fails
Debt is 7.93% and liquidity is 4.83%, but receivables plus cash are 38.85%, above the examined MSCI total-assets 33.33% limit. This is a calculation against the named method, not an index-membership claim; business allocation remains incomplete.
- Financial
- Pass
- Overall
- Incomplete
Debt is 7.93% and liquidity is 4.83%, below the examined 33% Malaysia SAC financial limits. This is a calculation against SAC ratios, not an official classification of a U.S.-listed security; screened business revenue remains unavailable.
- Financial
- Not calculated
- Overall
- Not calculated
A properly licensed and reproducible historical market-cap series is not stored, so these methods are not estimated from a current spot price.
Business-activity disclosure
McKesson distributes branded, generic, specialty and over-the-counter pharmaceuticals, medical supplies and healthcare technology and provides oncology, pharmacy and practice solutions. Healthcare logistics and medicines distribution are generally permissible commerce, while controlled-substance distribution, finance leases, late fees and customer end uses require qualitative review.
Limitation: The filing reports segment revenue and product/service categories but does not quantify a universal prohibited-revenue numerator by controlled substance, alcohol-containing product, payer, government contract, pharmacy, oncology treatment, finance lease or other end use.
Purification
McKesson discloses $179 million of interest income, or 0.04% of fiscal revenue, but does not quantify every finance charge, controlled-substance, product or customer end use. No fixed purification percentage is prescribed here; readers should follow the scholar or methodology they use.
Inputs, assumptions and primary sources
- Debt uses $6.526 billion of total debt outstanding at March 31, 2026, including current maturities and finance-lease obligations; operating lease obligations are not entered as conventional debt.
- Cash uses $3.975 billion of cash and cash equivalents. The filing says cash equivalents are primarily AAA-rated U.S. government money-market funds, short-term deposits and commercial paper issued by non-financial institutions; these are not added again as separate securities.
- Receivables use $27.985 billion of net receivables, primarily trade accounts receivable from customers and amounts due from suppliers. Physician-practice finance leases are disclosed separately and are not treated as a lending arm here.
- Revenue uses $403.430 billion for fiscal 2026 across pharmaceutical distribution, oncology and multispecialty, prescription technology and medical-surgical solutions.
- The filing discloses $179 million of interest income for fiscal 2026 and separately notes that finance charges to customers, primarily late fees, are included in other income. Only the disclosed interest-income line is used for the income screen.
- McKesson distributes medicines, medical supplies and healthcare technology, but the filing does not quantify every controlled-substance, payer, pharmacy, government, oncology or customer end use into a universal prohibited-revenue numerator.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Current quantitative screen
The calculations above use McKesson's official filing (fiscal 2026 Form 10-K for the year ended March 31, 2026). Amounts are in USD millions and use total assets as the denominator so the inputs can be reproduced.
- Interest-bearing debt / assets: 7.93%, using $6.526 billion of total debt.
- Cash and cash equivalents / assets: 4.83%, using $3.975 billion.
- Receivables plus cash / assets: 38.85%, using $27.985 billion of net receivables plus cash.
- Disclosed interest income / sales: 0.04%, using $179 million against $403.430 billion of fiscal revenue.
FTSE Yasaar and Malaysia SAC financial ratios pass on these inputs. MSCI total-assets fails because receivables plus cash is above its examined 33.33% limit. Market-cap denominator methods are not calculated because ZakatInvest does not store a licensed, reproducible historical market-cap series.
What McKesson does
McKesson's fiscal 2026 revenue was $403.430 billion across North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions and Medical-Surgical Solutions. The business distributes branded, generic, specialty, biosimilar and over-the-counter medicines and provides pharmacy, oncology, practice and healthcare technology services.
Healthcare logistics and supplying medicines are generally permissible commerce. The filing does not quantify every controlled-substance, pharmacy, oncology, payer, government or patient end use into a universal prohibited-revenue numerator, so the article does not claim zero haram revenue.
Ethical and qualitative questions
- Opioid history: McKesson has faced major opioid litigation and continues to distribute controlled substances. Current compliance systems and product-level mix require continuing review.
- Customer concentration: the top ten customers represented approximately 73% of fiscal revenue; CVS represented approximately 24%.
- Finance charges: interest income was $179 million, and other income includes finance charges primarily for customer late fees. Scholars can differ on how to treat those fees.
- Receivables and leases: most receivables are trade balances, while physician-practice finance leases and payment terms require methodology-specific review.
- Operations: drug shortages, recalls, pricing and reimbursement regulation, privacy, supply-chain resilience and patient safety remain material diligence issues.
Verdict: HALAL, methodology-dependent
McKesson is presented as HALAL on ZakatInvest's qualitative healthcare-distribution assessment, with FTSE Yasaar and Malaysia SAC financial ratios passing and the examined MSCI receivables-plus-cash screen failing. This is not official index membership or a fatwa. The medicines-distribution core is generally permissible, but controlled substances, finance charges, customer concentration and downstream use warrant scholar review.
Use the quantitative screen alongside the controlled-substance, late-fee, receivables and customer-concentration analysis and consult a qualified scholar for your chosen methodology.
Check another asset →